This study demonstrated that lornoxicam administered as a quick-release formulation is not inferior to the equivalent formulation of diclofenac potassium in terms of onset of PAR in patients ...

The following treatments were administered over a 7-day period: lornoxicam 8mg quick-release formulation or diclofenac potassium 50mg. On day 1, patients received in the clinic, no later than 2pm ...